Digital Diagnostics And AI Will Open Global Markets

Key Takeaways

• Global expansion and scalable manufacturing are set to boost long-term revenue growth, increase market share, and drive sustainable margin improvements.
  
• Innovative AI-enabled, cost-effective imaging offerings are positioned to expand addressable markets and generate new high-margin recurring revenue streams.
  
• Slow adoption of core imaging technology, ongoing losses, heavy reliance on teleradiology, regulatory hurdles, and high spending threaten profitability and growth prospects.

Catalysts

Develops a commercial-grade tomographic imaging device with a digital X-ray source.

• Rapid progress toward commercial deployment, with a clear pipeline to install 100 Nanox.ARC systems by year-end, is expected to significantly increase revenue in the second half of 2025 and beyond, especially as a growing number of units begin active scanning and utilization.
  
• Expansion into new geographies-including rapid entry into Europe post-CE Mark and upcoming launches in Romania, Greece, and Latin America-aligns with rising global healthcare investment in emerging markets, driving long-term revenue growth and global market share.
  
• Integration of AI and cloud-based teleradiology solutions through collaborations with academic centers and commercial partners is positioning Nano-X to benefit from the healthcare sector's shift towards digital diagnostics, which is likely to boost recurring revenue, improve gross margins, and support adoption in regions with radiologist shortages.
  
• The development of cost-effective, portable, and mobile imaging offerings-such as the mobile Nanox.ARC vehicle-directly addresses the need for affordable, accessible imaging (especially amid global population aging), which should expand the company's addressable market and create new high-margin service streams.
  
• Recent agreements for scalable manufacturing and supply chain robustness (e.g., partnership with Fabrinet) are set to lower production costs, support margin expansion, and mitigate operational risks, providing a pathway for sustainable improvements in net margins as commercial sales grow.

Nano-X Imaging Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Nano-X Imaging's revenue will grow by 102.4% annually over the next 3 years.
• Analysts are not forecasting that Nano-X Imaging will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Nano-X Imaging's profit margin will increase from -523.8% to the average US Healthcare industry of 6.1% in 3 years.
• If Nano-X Imaging's profit margin were to converge on the industry average, you could expect earnings to reach $7.3 million (and earnings per share of $0.09) by about July 2029, up from -$76.0 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 86.2x on those 2029 earnings, up from -1.1x today. This future PE is greater than the current PE for the US Healthcare industry at 24.5x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 8.58%, as per the Simply Wall St company report.

Risks

• Despite steady progress in system installations, only about 20 out of over 60 installed Nanox.ARC units were actually operational and scanning patients in Q2 2025, indicating slow commercial adoption and utilization, which negatively impacts near-term revenue growth and raises doubts about achieving scale and pathway to profitability.
  
• Nanox continues to incur significant net losses ($14.7 million in Q2 2025 versus $13.6 million in Q2 2024), with gross margins on core imaging system sales and AI solutions remaining negative, suggesting a high risk of prolonged unprofitability and continued cash burn that could lead to additional capital raises and potential shareholder dilution.
  
• The company's revenue growth remains heavily reliant on teleradiology services, which are not the core novel technology offering, while revenues from imaging system sales and AI solutions stay minimal and volatile, highlighting execution risk and potential overreliance on a commoditized service line that could constrain future earnings quality and consistency.
  
• Regulatory clearance and adoption remain highly region-dependent, with U.S. operations reportedly approved in only eight states and many global market launches still pending import permits or certifications, indicating long-term regulatory and commercialization uncertainty that could limit global revenue opportunities and delay scale.
  
• High R&D and sales and marketing spending, combined with slow revenue ramp-up from new product lines, poses a challenge to improving net margins and raises questions about the company's ability to achieve operational leverage, especially if evolving healthcare reimbursement or competitive activity delays broader acceptance and monetization of its technology.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $5.8 for Nano-X Imaging based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $7.4, and the most bearish reporting a price target of just $5.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $120.4 million, earnings will come to $7.3 million, and it would be trading on a PE ratio of 86.2x, assuming you use a discount rate of 8.6%.
• Given the current share price of $1.16, the analyst price target of $5.8 is 80.0% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.